Header Logo

Connection

THOMAS KOSTEN to Substance-Related Disorders

Back to Details
This is a "connection" page, showing publications THOMAS KOSTEN has written about Substance-Related Disorders.
THOMAS KOSTEN
Connection Strength
13.599
Substance-Related Disorders
  1. Vaccines as Immunotherapies for Substance Use Disorders. Am J Psychiatry. 2024 May 01; 181(5):362-371.
    View in: PubMed
    Score: 0.615
  2. Suicide Risk in a National VA Sample: Roles of Psychiatric Diagnosis, Behavior Regulation, Substance Use, and Smoking. J Clin Psychiatry. 2022 06 06; 83(3).
    View in: PubMed
    Score: 0.539
  3. Current status of vaccines for substance use disorders: A brief review of human studies. J Neurol Sci. 2022 Mar 15; 434:120098.
    View in: PubMed
    Score: 0.521
  4. Current status of immunotherapies for addiction. Ann N Y Acad Sci. 2021 04; 1489(1):3-16.
    View in: PubMed
    Score: 0.461
  5. Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists. Psychopharmacology (Berl). 2019 Oct; 236(10):2899-2907.
    View in: PubMed
    Score: 0.428
  6. Current status and future prospects for the development of substance abuse vaccines. Expert Rev Vaccines. 2017 11; 16(11):1067-1077.
    View in: PubMed
    Score: 0.389
  7. Pharmacologic management of comorbid post-traumatic stress disorder and addictions. Am J Addict. 2015 Dec; 24(8):705-12.
    View in: PubMed
    Score: 0.342
  8. Pharmacotherapy for stimulant-related disorders. Curr Psychiatry Rep. 2013 Nov; 15(11):415.
    View in: PubMed
    Score: 0.297
  9. Can you vaccinate against substance abuse? Expert Opin Biol Ther. 2013 Aug; 13(8):1093-7.
    View in: PubMed
    Score: 0.286
  10. Epigenetics of drug abuse: predisposition or response. Pharmacogenomics. 2012 Jul; 13(10):1149-60.
    View in: PubMed
    Score: 0.271
  11. Immunotherapy for drug abuse. CNS Neurol Disord Drug Targets. 2011 Dec; 10(8):876-9.
    View in: PubMed
    Score: 0.260
  12. Vaccines against drug abuse. Clin Pharmacol Ther. 2012 Jan; 91(1):60-70.
    View in: PubMed
    Score: 0.260
  13. Stress and addiction. Am J Psychiatry. 2011 Jun; 168(6):566-8.
    View in: PubMed
    Score: 0.251
  14. Prescription pain medication dependence. Am J Psychiatry. 2011 May; 168(5):466-71.
    View in: PubMed
    Score: 0.250
  15. Improving PTSD/substance abuse treatment in the VA: a survey of providers. Am J Addict. 2010 May-Jun; 19(3):257-63.
    View in: PubMed
    Score: 0.233
  16. Traditional medicine in the treatment of drug addiction. Am J Drug Alcohol Abuse. 2009; 35(1):1-11.
    View in: PubMed
    Score: 0.212
  17. Stereotactic neurosurgical treatment of drug addiction. Am J Drug Alcohol Abuse. 2009; 35(6):391-3.
    View in: PubMed
    Score: 0.212
  18. Substance abuse vaccines. Ann N Y Acad Sci. 2008 Oct; 1141:257-69.
    View in: PubMed
    Score: 0.209
  19. The future of vaccines in the management of addictive disorders. Curr Psychiatry Rep. 2007 Oct; 9(5):381-7.
    View in: PubMed
    Score: 0.195
  20. Pharmacotherapy for addictions: partnering with contingency management. Am J Drug Alcohol Abuse. 2007; 33(3):341-2.
    View in: PubMed
    Score: 0.185
  21. Pharmacotherapeutic environments for substance use disorders. Am J Drug Alcohol Abuse. 2007; 33(5):627-9.
    View in: PubMed
    Score: 0.185
  22. Human laboratory and neuroimaging studies in substance use disorders: developing new treatment approaches. Am J Drug Alcohol Abuse. 2007; 33(6):765-7.
    View in: PubMed
    Score: 0.185
  23. Therapeutic options and challenges for substances of abuse. Dialogues Clin Neurosci. 2007; 9(4):431-45.
    View in: PubMed
    Score: 0.185
  24. Immunotherapy for the treatment of drug abuse. Pharmacol Ther. 2005 Oct; 108(1):76-85.
    View in: PubMed
    Score: 0.170
  25. Future of anti-addiction vaccines. Stud Health Technol Inform. 2005; 118:177-85.
    View in: PubMed
    Score: 0.161
  26. Pharmacologic management of relapse prevention in addictive disorders. Psychiatr Clin North Am. 2004 Dec; 27(4):627-48.
    View in: PubMed
    Score: 0.160
  27. New medication strategies for comorbid substance use and bipolar affective disorders. Biol Psychiatry. 2004 Nov 15; 56(10):771-7.
    View in: PubMed
    Score: 0.160
  28. Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2004 Feb; 3(1):11-8.
    View in: PubMed
    Score: 0.151
  29. Correlates of Risk for Disinhibited Behaviors in the Million Veteran Program Cohort. JAMA Psychiatry. 2024 02 01; 81(2):188-197.
    View in: PubMed
    Score: 0.151
  30. Management of drug and alcohol withdrawal. N Engl J Med. 2003 May 01; 348(18):1786-95.
    View in: PubMed
    Score: 0.143
  31. Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2002 Oct; 1(3):363-71.
    View in: PubMed
    Score: 0.138
  32. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs. 2002 Apr; 11(4):491-9.
    View in: PubMed
    Score: 0.133
  33. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry. 2001 Aug; 158(8):1184-90.
    View in: PubMed
    Score: 0.127
  34. Contingency management interventions: from research to practice. Am J Psychiatry. 2001 May; 158(5):694-702.
    View in: PubMed
    Score: 0.125
  35. Cingulate Cortex Structural Alterations in Substance Use Disorder Psychiatric Inpatients. Am J Addict. 2021 01; 30(1):72-79.
    View in: PubMed
    Score: 0.121
  36. Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse. J Nerv Ment Dis. 2000 Jul; 188(7):454-9.
    View in: PubMed
    Score: 0.118
  37. Orbitofrontal, dorsal striatum, and habenula functional connectivity in psychiatric patients with substance use problems. Addict Behav. 2020 09; 108:106457.
    View in: PubMed
    Score: 0.116
  38. Depression and stimulant dependence: neurobiology and pharmacotherapy. J Nerv Ment Dis. 1998 Dec; 186(12):737-45.
    View in: PubMed
    Score: 0.106
  39. Addiction as a brain disease. Am J Psychiatry. 1998 Jun; 155(6):711-3.
    View in: PubMed
    Score: 0.102
  40. A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings. J Subst Abuse Treat. 1998 May-Jun; 15(3):261-5.
    View in: PubMed
    Score: 0.101
  41. The pharmacotherapy of relapse prevention using anticonvulsants. Am J Addict. 1998; 7(3):205-9.
    View in: PubMed
    Score: 0.099
  42. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997 Aug; 54(8):713-20.
    View in: PubMed
    Score: 0.096
  43. Dose dependent effects of yohimbine on methadone maintained patients. Am J Drug Alcohol Abuse. 1997 May; 23(2):327-33.
    View in: PubMed
    Score: 0.095
  44. Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study. J Neuropsychiatry Clin Neurosci. 1997; 9(1):29-36.
    View in: PubMed
    Score: 0.092
  45. Substance abuse and schizophrenia: editors' introduction. Schizophr Bull. 1997; 23(2):181-6.
    View in: PubMed
    Score: 0.092
  46. Abstinence symptomatology associated with cessation of chronic cocaine abuse among methadone-maintained patients. Am J Drug Alcohol Abuse. 1996 Aug; 22(3):377-88.
    View in: PubMed
    Score: 0.090
  47. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse. 1995 Nov; 21(4):469-81.
    View in: PubMed
    Score: 0.085
  48. Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders. Pharmacogenet Genomics. 2015 Jun; 25(6):296-304.
    View in: PubMed
    Score: 0.083
  49. A single-blind investigation of four auricular needle puncture configurations. Am J Chin Med. 1995; 23(2):105-14.
    View in: PubMed
    Score: 0.080
  50. Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance. Am J Drug Alcohol Abuse. 1994 Nov; 20(4):445-58.
    View in: PubMed
    Score: 0.080
  51. Stimulant withdrawal. Addiction. 1994 Nov; 89(11):1477-81.
    View in: PubMed
    Score: 0.080
  52. Cue-elicited cocaine craving and autogenic relaxation. Association with treatment outcome. J Subst Abuse Treat. 1994 Nov-Dec; 11(6):549-52.
    View in: PubMed
    Score: 0.080
  53. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend. 1994 Oct; 36(2):109-13.
    View in: PubMed
    Score: 0.079
  54. Cocaine abuse in methadone maintenance programs: integrating pharmacotherapy with psychosocial interventions. J Psychoactive Drugs. 1994 Apr-Jun; 26(2):137-46.
    View in: PubMed
    Score: 0.076
  55. Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications. Expert Opin Investig Drugs. 2013 Dec; 22(12):1549-68.
    View in: PubMed
    Score: 0.074
  56. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry. 1993 Jul 1-15; 34(1-2):66-74.
    View in: PubMed
    Score: 0.073
  57. Spirituality and confidence to resist substance use among celebrate recovery participants. J Relig Health. 2013 Mar; 52(1):107-13.
    View in: PubMed
    Score: 0.071
  58. Effects of sham and real auricular needling: implications for trials of acupuncture for cocaine addiction. Am J Chin Med. 1993; 21(2):103-11.
    View in: PubMed
    Score: 0.070
  59. Clinical and research perspectives on cocaine abuse: the pharmacotherapy of cocaine abuse. NIDA Res Monogr. 1993; 135:48-56.
    View in: PubMed
    Score: 0.070
  60. Gender differences in cocaine use and treatment response. J Subst Abuse Treat. 1993 Jan-Feb; 10(1):63-6.
    View in: PubMed
    Score: 0.070
  61. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry. 1992 Nov; 49(11):894-8.
    View in: PubMed
    Score: 0.069
  62. Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings. Biol Psychiatry. 1992 Sep 15; 32(6):523-8.
    View in: PubMed
    Score: 0.069
  63. Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics. Recent Dev Alcohol. 1992; 10:115-28.
    View in: PubMed
    Score: 0.065
  64. Treatment of dual diagnosis patients: a relapse prevention group approach. J Subst Abuse Treat. 1992; 9(4):305-9.
    View in: PubMed
    Score: 0.065
  65. Pharmacological approaches to cocaine dependence. Clin Neuropharmacol. 1992; 15 Suppl 1 Pt A:70A-71A.
    View in: PubMed
    Score: 0.065
  66. Buprenorphine for cocaine and opiate dependence. Psychopharmacol Bull. 1992; 28(1):15-9.
    View in: PubMed
    Score: 0.065
  67. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J Psychoactive Drugs. 1991 Oct-Dec; 23(4):417-25.
    View in: PubMed
    Score: 0.064
  68. Pharmacological blocking agents for treating substance abuse. J Nerv Ment Dis. 1991 Oct; 179(10):583-92.
    View in: PubMed
    Score: 0.064
  69. Medications development and the war on drugs: victims of the Gulf war? Biol Psychiatry. 1991 Mar 15; 29(6):521-3.
    View in: PubMed
    Score: 0.062
  70. Depression as a prognostic factor for pharmacological treatment of cocaine dependence. Psychopharmacol Bull. 1991; 27(3):337-43.
    View in: PubMed
    Score: 0.061
  71. Client issues in drug abuse treatment: addressing multiple drug abuse. NIDA Res Monogr. 1991; 106:136-51.
    View in: PubMed
    Score: 0.061
  72. SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry. 1991; 15(5):649-62.
    View in: PubMed
    Score: 0.061
  73. Anti-cocaine vaccine development. Expert Rev Vaccines. 2010 Sep; 9(9):1109-14.
    View in: PubMed
    Score: 0.060
  74. The SCID: a clinical instrument for assessing psychiatric disorders. NIDA Res Monogr. 1990; 105:213-9.
    View in: PubMed
    Score: 0.057
  75. Mazindol treatment of cocaine abuse. A double-blind investigation. NIDA Res Monogr. 1990; 105:514.
    View in: PubMed
    Score: 0.057
  76. Cocaine symptoms are predicted by familial psychopathology. NIDA Res Monogr. 1990; 105:603-4.
    View in: PubMed
    Score: 0.057
  77. The dependence syndrome concept as applied to alcohol and other substances of abuse. Recent Dev Alcohol. 1990; 8:47-68.
    View in: PubMed
    Score: 0.057
  78. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990; 16(3-4):329-36.
    View in: PubMed
    Score: 0.057
  79. Cocaine abuse and opioid withdrawal. Lancet. 1989 Jul 15; 2(8655):165-6.
    View in: PubMed
    Score: 0.055
  80. Pharmacotherapeutic interventions for cocaine abuse. Matching patients to treatments. J Nerv Ment Dis. 1989 Jul; 177(7):379-89.
    View in: PubMed
    Score: 0.055
  81. Inpatient vs. outpatient cocaine abuse treatments. NIDA Res Monogr. 1989; 95:312-3.
    View in: PubMed
    Score: 0.053
  82. Buprenorphine treatment of cocaine abuse. NIDA Res Monogr. 1989; 95:461.
    View in: PubMed
    Score: 0.053
  83. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 1989; 44(13):887-92.
    View in: PubMed
    Score: 0.053
  84. Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up. J Nerv Ment Dis. 1988 Mar; 176(3):176-81.
    View in: PubMed
    Score: 0.050
  85. Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse. 1988; 14(3):335-46.
    View in: PubMed
    Score: 0.050
  86. Differential diagnosis of psychiatric comorbidity in substance abusers. J Subst Abuse Treat. 1988; 5(4):201-6.
    View in: PubMed
    Score: 0.050
  87. Substance-use disorders in DSM-III-R. Evidence for the dependence syndrome across different psychoactive substances. Br J Psychiatry. 1987 Dec; 151:834-43.
    View in: PubMed
    Score: 0.049
  88. A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. J Clin Psychiatry. 1987 Nov; 48(11):442-4.
    View in: PubMed
    Score: 0.049
  89. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007 Apr; 164(4 Suppl):5-123.
    View in: PubMed
    Score: 0.047
  90. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped? Arch Gen Psychiatry. 1987 Mar; 44(3):281-4.
    View in: PubMed
    Score: 0.047
  91. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007 Jan 16; 146(2):116-27.
    View in: PubMed
    Score: 0.046
  92. Association of spirituality and sobriety during a behavioral spirituality intervention for Twelve Step (TS) recovery. Am J Drug Alcohol Abuse. 2007; 33(4):611-7.
    View in: PubMed
    Score: 0.046
  93. The dependence syndrome across different psychoactive substances: revised DSM-III. NIDA Res Monogr. 1987; 76:255-8.
    View in: PubMed
    Score: 0.046
  94. Diagnosing depression with the DST and TRH in cocaine and opioid abusers. J Subst Abuse Treat. 1986; 3(1):47-9.
    View in: PubMed
    Score: 0.043
  95. Abuse of cocaine with opioids: psychological aspects of treatment. NIDA Res Monogr. 1986; 67:278-82.
    View in: PubMed
    Score: 0.043
  96. Chronic naltrexone effect on cortisol. NIDA Res Monogr. 1986; 67:362-5.
    View in: PubMed
    Score: 0.043
  97. Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. Am J Drug Alcohol Abuse. 1986; 12(1-2):1-16.
    View in: PubMed
    Score: 0.043
  98. Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry. 2004 Nov 15; 56(10):703-13.
    View in: PubMed
    Score: 0.040
  99. Relationship of depression to clonidine detoxification of opiate addicts. Compr Psychiatry. 1984 Sep-Oct; 25(5):503-8.
    View in: PubMed
    Score: 0.039
  100. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 2004 Aug 16; 75(2):123-34.
    View in: PubMed
    Score: 0.039
  101. Concurrent validity of the addiction severity index. J Nerv Ment Dis. 1983 Oct; 171(10):606-10.
    View in: PubMed
    Score: 0.037
  102. [123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology (Berl). 1998 Jun; 137(4):321-5.
    View in: PubMed
    Score: 0.025
  103. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol Psychiatry. 1998 Apr 01; 43(7):540-3.
    View in: PubMed
    Score: 0.025
  104. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology. 1998 Mar; 18(3):135-74.
    View in: PubMed
    Score: 0.025
  105. Prognostic factors in Buprenorphine- versus methadone-maintained patients. J Nerv Ment Dis. 1998 Jan; 186(1):35-43.
    View in: PubMed
    Score: 0.025
  106. Effect of alpha-methyl-para-tyrosine on response to cocaine challenge. Biol Psychiatry. 1997 Aug 01; 42(3):181-90.
    View in: PubMed
    Score: 0.024
  107. Pharmacotherapy for opioid and cocaine abuse. Med Clin North Am. 1997 Jul; 81(4):909-25.
    View in: PubMed
    Score: 0.024
  108. Motivational factors in cocaine pharmacotherapy trials with methadone-maintained patients: problems and paradoxes. J Psychoactive Drugs. 1997 Apr-Jun; 29(2):205-12.
    View in: PubMed
    Score: 0.024
  109. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 1995 Dec; 40(2):125-31.
    View in: PubMed
    Score: 0.021
  110. Reliability of sequential naloxone challenge tests. Am J Drug Alcohol Abuse. 1995 Nov; 21(4):453-67.
    View in: PubMed
    Score: 0.021
  111. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. J Subst Abuse Treat. 1995 Nov-Dec; 12(6):423-8.
    View in: PubMed
    Score: 0.021
  112. Mazindol treatment for cocaine dependence. Drug Alcohol Depend. 1995 Oct; 39(3):245-52.
    View in: PubMed
    Score: 0.021
  113. Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control. J Subst Abuse Treat. 1995 May-Jun; 12(3):195-205.
    View in: PubMed
    Score: 0.021
  114. Tryptophan depletion and attenuation of cue-induced craving for cocaine. Am J Psychiatry. 1995 May; 152(5):778-83.
    View in: PubMed
    Score: 0.021
  115. Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry. 1995 Apr 15; 37(8):560-3.
    View in: PubMed
    Score: 0.021
  116. Differences between responders and nonresponders to cocaine cues in the laboratory. Addict Behav. 1995 Mar-Apr; 20(2):215-24.
    View in: PubMed
    Score: 0.020
  117. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Arch Gen Psychiatry. 1994 Sep; 51(9):713-9.
    View in: PubMed
    Score: 0.020
  118. Changes concurrent with initiation of abstinence from cocaine abuse. J Subst Abuse Treat. 1993 Nov-Dec; 10(6):577-83.
    View in: PubMed
    Score: 0.019
  119. Alprazolam and benzodiazepine dependence. J Clin Psychiatry. 1993 Oct; 54 Suppl:64-75; discussion 76-7.
    View in: PubMed
    Score: 0.018
  120. Dopaminergic responsivity during cocaine abstinence: a pilot study. Psychiatry Res. 1992 Jul; 43(1):77-85.
    View in: PubMed
    Score: 0.017
  121. Buprenorphine: beyond methadone? Hosp Community Psychiatry. 1991 Apr; 42(4):347-9.
    View in: PubMed
    Score: 0.016
  122. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990; 7(1):51-4.
    View in: PubMed
    Score: 0.014
  123. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry. 1989 Feb; 46(2):117-21.
    View in: PubMed
    Score: 0.013
  124. Double-blind evaluation of the effect of acute amantadine on cocaine craving. Psychopharmacology (Berl). 1989; 97(3):402-3.
    View in: PubMed
    Score: 0.013
  125. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict. 1988 May; 83(5):567-75.
    View in: PubMed
    Score: 0.013
  126. A field trial of DSM-III-R psychoactive substance dependence disorders. Am J Psychiatry. 1987 Mar; 144(3):351-5.
    View in: PubMed
    Score: 0.012
  127. Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study. Arch Gen Psychiatry. 1986 Aug; 43(8):739-45.
    View in: PubMed
    Score: 0.011
  128. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998 Aug; 105(2):100-5.
    View in: PubMed
    Score: 0.006
  129. Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology (Berl). 1995 May; 119(2):179-85.
    View in: PubMed
    Score: 0.005
  130. Psychiatric disorders in relatives of probands with opiate addiction. Arch Gen Psychiatry. 1991 Jan; 48(1):33-42.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.